Asenapine: a novel psychopharmacologic agent with a unique human receptor signature
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Asenapine is a novel psychopharmacologic agent under development for the treatment of schizophrenia and bipolar disorder. We determined and compared the human receptor binding affinities and functional characteristics of asenapine and several antipsychotic drugs. Compounds were tested under comparable assay conditions using cloned human receptors. In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (p K i) for serotonin receptors (5-HT 1A [8.6], 5-HT 1B [8.4], 5-HT 2A [10.2], 5-HT 2B [9.8], 5-HT 2C [10.5], 5-HT 5 [8.8], 5-HT 6 [9.6] and 5-HT 7 [9.9]), adrenoceptors (α 1 [8.9], α 2A [8.9], α 2B [9.5] and α 2C [8.9]), dopamine receptors (D 1 [8.9], D 2 [8.9], D 3 [9.4] and D 4 [9.0]) and histamine receptors (H 1 [9.0] and H 2 [8.2]). It had much lower affinity (p K i ≤ 5) for muscarinic receptors and was the only agent with affinity for H 2 receptors. Relative to its D 2 receptor affinity, asenapine had a higher affinity for 5-HT 2C, 5-HT 2A, 5-HT 2B, 5-HT 7, 5-HT 6, α 2B and D 3 receptors, suggesting stronger engagement of these targets at therapeutic doses. Asenapine behaved as a potent antagonist (p K B) at 5-HT 1A (7.4), 5-HT 1B (8.1), 5-HT 2A (9.0), 5-HT 2B (9.3), 5-HT 2C (9.0), 5-HT 6 (8.0), 5-HT 7 (8.5), D 2 (9.1), D 3 (9.1), α 2A (7.3), α 2B (8.3), α 2C (6.8) and H 1 (8.4) receptors. These functional effects differed from those of risperidone (p K B < 5 for 5-HT 6) and olanzapine (p K B < 5 for 5-HT 1A and α 2). Our results indicate that asenapine has a unique human receptor signature, with binding affinity and antagonistic properties that differ appreciably from those of antipsychotic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,062
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Serotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715
Mathur, R. (2004) · Drug Screening Methods · doi:10.5005/jp/books/10243_6 · Cited by 665
Binding of antipsychotic drugs to human brain receptors
Richelson, E., & Souder, T. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00911-5 · Cited by 607
Functional, molecular and pharmacological advances in 5-HT receptor research
HEDLUND, P., & SUTCLIFFE, J. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.07.002 · Cited by 350
Woolley, M., Marsden, C., & Fone, K. (2004) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007043482561 · Cited by 302
Roth, B., Hanizavareh, S. M., & Blum, A. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1683-8 · Cited by 257
Dopamine D3 receptor antagonists as therapeutic agents
Joyce, J. N., & Millan, M. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03491-4 · Cited by 237
Guscott, M., Bristow, L. J., Hadingham, K., Rosahl, T. W., Beer, M. S., Stanton, J. A., Bromidge, F., Owens, A. P., Huscroft, I., Myers, J., et al. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.11.015 · Cited by 231
Serotonergic basis of antipsychotic drug effects in schizophrenia
Lieberman, J. A., Mailman, R. B., Duncan, G., Sikich, L., Chakos, M., Nichols, D. E., & Kraus, J. E. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00187-5 · Cited by 206
Possible implications of the dopamine D3 receptor in schizophrenia and in antipsychotic drug actions
Schwartz, J. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00043-0 · Cited by 191
Thomas, D., & Hagan, J. (2004) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007043482633 · Cited by 183
Potkin, S. G., & Cohen, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1004 · Cited by 175
Contributions of 5-HT2C receptors to multiple actions of central serotonin systems
Giorgetti, M., & Tecott, L. H. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.01.036 · Cited by 173
α-Adrenoceptor modulation hypothesis of antipsychotic atypicality
Svensson, T. H. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.009 · Cited by 156
Metabolic risk during antipsychotic treatment
Newcomer, J. W. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.12.003 · Cited by 141
Management of the Negative Symptoms of Schizophrenia: New Treatment Options
M??ller, H.-J. (2003) · CNS Drugs · doi:10.2165/00023210-200317110-00003 · Cited by 141
Reynolds, G. P., Yao, Z., Zhang, X., Sun, J., & Zhang, Z. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.07.001 · Cited by 132
Johnson, D. E., Yamazaki, H., Ward, K. M., Schmidt, A. W., Lebel, W. S., Treadway, J. L., Gibbs, E. M., Zawalich, W. S., & Rollema, H. (2005) · Diabetes · doi:10.2337/diabetes.54.5.1552 · Cited by 132
A Comparative Review of New Antipsychotics
Blin, O. (1999) · The Canadian Journal of Psychiatry · doi:10.1177/070674379904400303 · Cited by 130
Current and Novel Approaches to the Drug Treatment of Schizophrenia
Rowley, M., Bristow, L. J., & Hutson, P. H. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0002432 · Cited by 129
Predictive value of cognition for different domains of outcome in recent-onset schizophrenia
Holthausen, E. A. E., Wiersma, D., Cahn, W., Kahn, R. S., Dingemans, P. M. A. J., Schene, A. H., & van den Bosch, R. J. (2006) · Psychiatry Research · doi:10.1016/j.psychres.2005.07.037 · Cited by 126
Describing an Atypical Antipsychotic: Receptor Binding and Its Role in Pathophysiology
Stahl, S. M. (2003) · The Primary Care Companion to The Journal of Clinical Psychiatry · Cited by 103
Atypical antipsychotic drug actions: unitary or multiple mechanisms for ‘atypicality’?
Roth, B. L., Sheffler, D. J., & Potkin, S. G. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00021-5 · Cited by 92
Understanding antipsychotic “atypicality”: a clinical and pharmacological moving target
Remington, G. (2003) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0334 · Cited by 89
Stip, É. (2006) · L Encéphale · doi:10.1016/s0013-7006(06)76162-0 · Cited by 87
Safety of Available Agents Used to Treat Bipolar Disorder: Focus on Weight Gain
Nemeroff, C. B. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0506 · Cited by 86
Marcus, M. M., Jardemark, K. E., Wadenberg, M.-L., Langlois, X., Hertel, P., & Svensson, T. H. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005328 · Cited by 83
Quality of life and functioning ability in subjects vulnerable to psychosis
Svirskis, T., Korkeila, J. A., Heinimaa, M., Huttunen, J., Ilonen, T., Ristkari, T., Hietala, J. A., Syvälahti, E. K. G., McGlashan, T. H., Vahlberg, T. J., et al. (2007) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2006.10.008 · Cited by 76
Möller, H., Bottlender, R., Wegner, U., Wittmann, J., & Strauß, A. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.00010.x · Cited by 73
Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics
Lane, H., Lee, C.-C., Liu, Y., & Chang, W. (2005) · Pharmacogenomics · doi:10.1517/14622416.6.2.139 · Cited by 57
Dopamine and glutamate dysfunctions in schizophrenia: Role of the dopamine D3 receptor
Leriche, L., Díaz, J., & Sokoloff, P. (2004) · Neurotoxicity Research · doi:10.1007/bf03033298 · Cited by 29
Antipsychotic Drugs: Evolving Mechanisms of Action with Improved Therapeutic Benefits
Dean, B., & Scarr, E. (2004) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007043337373 · Cited by 28
Pharmacological treatment strategies for schizophrenia
Lindenmayer, J., & Khan, A. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.4.705 · Cited by 22
Cited by
Vitaku, E., Smith, D. T., & Njardarson, J. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501100b · Cited by 6,418
Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms
Reynolds, G. P., & Kirk, S. L. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.10.010 · Cited by 401
Kiss, B., Horváth, A., Némethy, Z., Schmidt, É., Laszlovszky, I., Bugovics, G., Fazekas, K., Hornok, K., Orosz, S., Gyertyán, I., et al. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.160432 · Cited by 367
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270
Citrome, L. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02228.x · Cited by 266
Metadata
- Authors
- Shahid, M., Walker, G., Zorn, S., & Wong, E.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2008-02-28
- Volume
- 23
- Issue
- 1
- Pages
- 65-73
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2147015928
- Cited by
- 493
- References
- 40
- FWCI
- 15.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.